Insider Transactions in Q3 2022 at Evolus, Inc. (EOLS)
Insider Transaction List (Q3 2022)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 15
2022
|
Medytox Inc. |
SELL
Open market or private sale
|
Direct |
24,000
-0.33%
|
$240,000
$10.34 P/Share
|
|
Sep 14
2022
|
Medytox Inc. |
SELL
Open market or private sale
|
Direct |
73,000
-0.99%
|
$730,000
$10.27 P/Share
|
|
Sep 12
2022
|
Robert Hayman Director |
BUY
Open market or private purchase
|
Indirect |
1,091
+9.84%
|
$10,910
$10.78 P/Share
|
|
Sep 09
2022
|
Robert Hayman Director |
BUY
Open market or private purchase
|
Indirect |
8,909
+50.0%
|
$89,090
$10.35 P/Share
|
|
Sep 09
2022
|
Medytox Inc. |
SELL
Open market or private sale
|
Direct |
20,700
-0.28%
|
$207,000
$10.53 P/Share
|
|
Sep 08
2022
|
Medytox Inc. |
SELL
Open market or private sale
|
Direct |
15,300
-0.21%
|
$153,000
$10.39 P/Share
|
|
Sep 07
2022
|
Robert Hayman Director |
BUY
Open market or private purchase
|
Direct |
4,967
+11.08%
|
$49,670
$10.05 P/Share
|
|
Sep 06
2022
|
Simone Blank Director |
BUY
Open market or private purchase
|
Direct |
20,000
+26.71%
|
$180,000
$9.24 P/Share
|
|
Sep 06
2022
|
Peter C Farrell Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+50.0%
|
$90,000
$9.1 P/Share
|
|
Sep 05
2022
|
Sandra Beaver Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,443
+50.0%
|
-
|
|
Aug 01
2022
|
Medytox Inc. |
SELL
Open market or private sale
|
Direct |
26,000
-0.35%
|
$338,000
$13.28 P/Share
|